Alphabetical list:
A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9
News: November 23, 2009
Genetic Variant Slows AIDS Progression
November 23, 2009Scientists report that a genetic variation appears to play a major role in slowing disease progression in HIV-infected patients.
In fact, those with the variation appear to take years longer to develop AIDS and die of complications of the disease.
"We're honing in on factors that vary across individuals that make a person more or less susceptible to HIV, in terms of how rapidly someone develops the disease," said study co-author Mary Carrington, a senior principal investigator at the U.S. National Cancer Institute.
However, this new knowledge won't translate into immediate benefits for patients with HIV.
AIDS remains a major killer in many parts of the world, but HIV - the virus that causes it - doesn't affect infected people the same way. "People progress to AIDS at hugely different rates," Carrington explained. "Some people progress within a year, while some have been infected for 20 years and still control the virus and don't have the disease."
It appears that three factors affect how the disease strikes a person, she said. One is the environment: the world in which a person lives. Another is the patient's genetic makeup. And the third is the genetic makeup of the virus itself.
In the study, published in the Nov. 22 online edition of Nature Genetics, Carrington and colleagues looked at genetic and medical records for hundreds of HIV-infected men. They were trying to see if genetic variations affected how the men fared.
The researchers found that a variation linked to higher levels of a protein known as HLA-C boosted the men's ability to avoid progressing to AIDS. It appeared to delay both the progression to AIDS and to death by years, Carrington said.
The genetic variation makes it easier for the immune system to kill cells that have been infected with the virus, she said. It does this by allowing immune cells to gain greater access to the infected cells, she explained.
Carrington said this genetic variation isn't related to another gene-related trait that makes some people virtually immune to HIV.
The study "hints at ways we might ultimately develop a vaccine or immune-based therapies that could modify or maybe even prevent the development of HIV disease," said Rowena Johnston, vice president of research with the Foundation for AIDS Research in New York City.
"The finding that a single piece of DNA can be strongly associated with something as complex as the control of HIV soon after infection is especially intriguing, not least because we know that early control of infection sets the stage for the entire course of the disease," Johnston noted.
What's next? The ultimate goal, Carrington said, is "to have a complete list of every genetic variance that is affecting how rapidly the disease develops."
That, in turn, could help physicians figure out how to better treat patients.
Archive issues: (50)
Archive list: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 [16] 17
October 17, 2011 | Sen. Grassley Seeks FDA Scrutiny of Paxil and Suicide RiskWASHINGTON, June 12, 2008 Senator Chuck Grassley has asked the Food and Drug Administration to carefully scrutinize information it received from drug maker GlaxoSmithKline about the anxiety disorder drug Paxil, based on the contents of a newly available report ...
September 21, 2009 | Topical cream studied for erectile dysfunctionScientists from Albert Einstein College of Medicine of Yeshiva University are working on a cream to rub on and treat erectile dysfunction (ED). The cream could prove to be safer than oral medications used to deliver nitric oxide to the cells that improves blood flow to treat impotency. Using ...
May 21, 2012 | Onyx Rises on Analyst View of Blood Cancer DrugNEW YORK -- Onyx Pharmaceuticals Inc. shares rose Thursday after a Bernstein Research analyst started covering the stock with an "Outperform" rating, saying he thinks the company’s blood cancer drug candidate will reach $1 billion in annual sales by ...
Related articles:
Chronic bacterial prostatitis - treatment
Treatment requires prolonged courses (4-8 weeks) of antibiotics that penetrate the prostate well (?-lactams and nitrofurantoin are ineffective). These include quinolones (ciprofloxacin, levofloxacin), sulfas (Bactrim, Septra) and macrolides (erythromycin, clarithromycin). Persistent infections may be helped in 80% of patients by the use of alpha blockers (tamsulosin (Flomax), alfuzosin), or long ...Section: Prostatitis
About interstitial cystitis/painful bladder syndrome
Interstitial cystitis/painful bladder syndrome (commonly abbreviated to "IC/PBS"), is a urinary bladder disease of unknown cause characterised by pain associated with urination (dysuria), urinary frequency (as often as every 10 minutes), urgency, and pressure in the bladder and/or pelvis. Pain that worsened with a certain food or drink and/or worsened with bladder filling and/or improved with urination was reported by 97% of patients. Patients may also experience nocturia, pelvic floor ...Section: Interstitial cystitis
Overview and symptoms
Erectile dysfunction is characterized by the regular or repeated inability to obtain or maintain an erection. There are several ways that erectile dysfunction is analyzed: Obtaining full erections at some times, such as when asleep (when the mind and psychological issues, if any, are less present), tends to suggest the physical structures are functionally working. However, the opposite case, a lack of nocturnal erections, does not imply the opposite, since a significant proportion of ...Section: Erectile Dysfunction